The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 05, 2014

Filed:

Aug. 02, 2013
Applicant:

Adamas Pharmaceuticals, Inc., Emeryville, CA (US);

Inventors:

Gregory T. Went, Mill Valley, CA (US);

Timothy J. Fultz, Pleasant Hill, CA (US);

Seth Porter, San Carlos, CA (US);

Laurence R. Meyerson, Las Vegas, NV (US);

Timothy S. Burkoth, Lake Bluff, IL (US);

Assignee:

Adamas Pharmaceutical, Inc., Emeryville, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/13 (2006.01); A61K 31/195 (2006.01); A61K 9/20 (2006.01); A61K 31/198 (2006.01); A61K 9/16 (2006.01); A61K 9/28 (2006.01); A61K 45/06 (2006.01); A61K 31/197 (2006.01); A61K 9/50 (2006.01);
U.S. Cl.
CPC ...
A61K 31/197 (2013.01); A61K 31/13 (2013.01); A61K 9/2054 (2013.01); A61K 31/198 (2013.01); A61K 9/2009 (2013.01); A61K 9/1617 (2013.01); A61K 9/2846 (2013.01); A61K 45/06 (2013.01); A61K 9/5047 (2013.01); A61K 9/1652 (2013.01); A61K 9/5078 (2013.01);
Abstract

A method of administering amantadine is provided. The method comprises orally administering to a subject a pharmaceutical composition comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of the amantadine. A dose of the composition provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the change in amantadine plasma concentration provided by a dose of the same quantity of an immediate release form of amantadine. The change in plasma concentration over time (dC/dT) is measured in a single dose human pharmacokinetic study in a defined time period of 0 to 4 hours after administration. The amantadine, or pharmaceutically acceptable salt thereof, is administered once daily at a dose of 300 to 500 mg per day.


Find Patent Forward Citations

Loading…